Duke University

Ohio State Innovation Foundation

Bruce A Sullenger

Christopher P Rusconi

Jaewoo Lee

Sabah Oney

Kam W Leong

Bethany Gray

Shahid M Nimjee

Juliana Layzer

Daniel George

Jennifer Freedman

Bonnie Lacroix

Brendon Patierno

Steven R Patierno

Michael Goldstein

Michael Kastan

Johannes Urban

Tung Suet Ruby Lam

Hemraj A Juwarker

Nanette Que-Gewirth

George A Pitoc

Timothy Robinson

Kristin Bompiani

Jennifer Gamboa Jackman

Kady-Ann C Steen-Burrell

Bethany Powell Gray

Elizabeth D Pratico

Victor J Dzau

Conrad P Hodgkinson

Michael D Nichols

Steven Patierno

Jennifer G Jackman

Erin Soule

Michael Nichols

Jens Lohrmann

James Frederiksen

Nanette L S Que-Gewirth

Rebekah R White

Youngju Lee

Disclosed herein are polycationic microfibers comprising a high-aspect-ratio polymeric core, the polymeric core comprising a blend of a first core polymer and a second core polymer, and a polycationic polymer immobilized on the surface of the polymeric core. The polycationic microfibers are capable of sequestering or clearing nucleic acids, proteins, biomolecular complexes, exosomes, or microparticles from solutions and samples and may be formed into filters or integrated into filtration apparatuses. Also disclosed are methods for sequestering or clearing solutes from solutions and fluids, methods for the treatment of diseases or conditions, and methods for the prevention of diseases or conditions.

Polycationic microfibers and methods of using the same

Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.

Antidote-mediated reversal of extracellular aptamer staining

Provided herein are compositions including aptamers capable of binding to and/or inhibiting the activity of nucleolin. Methods of treating cancer in a subject by administering such compositions are also provided.

Nucleolin-targeting aptamers and methods of using the same

The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Splice-switching oligonucleotides and methods of use

Provided herein are aptamers capable of inhibiting the activity of Von Willebrand Factor (VWF). Pharmaceutical compositions comprising these aptamers are also provided. Methods of preventing blood clot formation in a subject by administering the aptamers are provided and methods of treating a blood clot by administering a VWF-targeting agent are also provided.

Von Willebrand Factor (VWF)-targeting agents and methods of using the same

The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid ('nucleic acid binding agent'), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

Inhibition of endosomal toll-like receptor activation

Disclosed herein are compositions and methods for inhibiting the growth of cells or inducing cell death. The composition capable of inhibiting the growth of cells or inducing cell death comprises a 5'-triphosphate non-linear RNA. The RNA comprises a first stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and may optionally comprise a second stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and a spacer between the first stem-loop and the second stem loop. Methods for inhibiting the growth of cells or inducing cell death comprise contacting cells with the composition or administering the composition to a subject in an amount effective to inhibit the growth of the cells or induce death of the cells.

Compositions and methods for differential induction of cell death and interferon expression

Provided herein are imaging agents, antidotes to the imaging agents and methods of using the same to image a thrombus or blood clot or thrombin including sites of thrombin accumulation and to diagnose and treat thrombosis. The imaging agents include an aptamer capable of binding the thrombus or thrombin in particular linked to a reporter moiety. The imaging agents may be used to label the thrombus or sites of thrombin accumulation. Antidotes capable of binding to the aptamer in the imaging agent are also provided. The antidotes may further be linked to a quencher capable of quenching the reporter moiety.

Thrombus imaging aptamers and methods of using same

Disclosed herein are compositions and methods for cellular reprogramming. The compositions comprise one or more miRs and an activator of NF&#x3ba;B. Also provided are methods for enhancing or upregulating cardiomyocyte maturation in a cell or a subject and methods for inhibiting or downregulating cardiomyocyte maturation.

Compositions and methods for cellular reprogramming

Von Willebrand Factor (VWF)&#x2014;targeting agents and methods of using the same

Methods of making polycationic nanofibers by grafting cationic polymers onto electrospun neutral nanofibers and polycationic nanofibers produced by the methods are provided herein. In addition, methods of using the polycationic nanofibers to reduce inflammation, to adsorb anionic compounds such as heparin or nucleic acids, to inhibit the growth of microbes or inhibit the formation of a biofilm are also provided. The polycationic nanofibers may be in a mesh and may be included in a medical device, wound dressing, bandage, or as part of a graft.

Electrospun cationic nanofibers and methods of making and using the same

Growing community of inventors

Chapel Hill, NC, United States of America

Bruce A Sullenger